EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Activation of PDE2A moderates pathologically high cAMP/PKA responses to dopamine in dyskinetic mice

Ségolène Bompierre, Cédric Yapo, Régis Blaise, Pierre Vincent, Liliana R V Castro

Neurobiology of Disease · 2025

DOI: 10.1016/j.nbd.2025.106968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurobiology of Disease, 2025. Verfasst von Ségolène Bompierre und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, F…. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 2, Cyclic AMP-Dependent Protein Kinases, Cyclic AMP, Dopamine. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: French Association for Parkinson's Disease, French National Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dopamine depletion in Parkinson's disease (PD) leads to severe motor and cognitive disturbances. While L-DOPA replacement therapy efficiently alleviates the motor symptoms, it leads to long-term complications, notably dyskinesia. These deregulations are closely associated with an exacerbated cAMP/PKA signaling and alterations in striatal plasticity. In this study we used genetically encoded biosensors to monitor cAMP and PKA signals in the 6-OHDA mouse model of Parkinson's disease. In these mice cAMP levels and PKA signaling were markedly up-regulated. We observed that stimulation of the cGMP signaling by a NO donor, DEANO, efficiently down-regulated the amplitude of these hypersensitive responses and this regulatory effect was mediated by PDE2A. Indeed, the stimulation of PDE2A by cGMP was found to efficiently reduce the excessive cAMP/PKA signaling triggered by D1 receptor stimulation, and this, despite unaltered PDE2A expression. These findings strongly suggest that boosting PDE2A activity in the striatum would be of therapeutic value to moderate the excessive cAMP/PKA responses and mitigate the long-term changes in striatal neurons associated with the adverse effects of L-DOPA treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclic Nucleotide Phosphodiesterases, Type 2Cyclic AMP-Dependent Protein KinasesCyclic AMPDopamineParkinsonian DisordersAnimalsMiceOxidopamineSignal TransductionMice, Inbred C57BLCorpus StriatumMaleDisease Models, AnimalCyclic GMPLevodopa

Stichwörter der Autor:innen

Cyclic AMPCyclic GMPDopamineL-DOPA-induced dyskinesiaParkinson's diseasePhosphodiesterases

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 2Cyclic AMP-Dependent Protein KinasesCyclic AMPDopamineOxidopaminePde2a protein, mouseCyclic GMPLevodopa

Autor:innen und Institutionen

  • Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France. Electronic address: segolene.bompierre@donders.ru.nl.
  • Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France. Electronic address: yapoced@yahoo.fr.
  • Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France. Electronic address: regis.blaise@sorbonne-universite.fr.
  • Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France; IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France. Elec…
  • Sorbonne Université, CNRS, Inserm, Institut de Biologie Paris Seine (IBPS), Center for Neuroscience at Sorbonne Université (NeuroSU), 75005, Paris, France. Electronic address: liliana.ribeiro_vivas_de_castro@sorbonne-un…

Förderung

  • French Association for Parkinson's Disease
  • French National Research Agency

Zitieren

APA

Bompierre, S., Yapo, C., Blaise, R., Vincent, P., & Castro, L. R. V. (2025). Activation of PDE2A moderates pathologically high cAMP/PKA responses to dopamine in dyskinetic mice. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2025.106968

Vancouver

Bompierre S, Yapo C, Blaise R, Vincent P, Castro LRV. Activation of PDE2A moderates pathologically high cAMP/PKA responses to dopamine in dyskinetic mice. Neurobiology of Disease. 2025. doi:10.1016/j.nbd.2025.106968

BibTeX
@article{Bompierre2025,
  author = {Bompierre, Ségolène and Yapo, Cédric and Blaise, Régis and Vincent, Pierre and Castro, Liliana R V},
  title = {Activation of PDE2A moderates pathologically high cAMP/PKA responses to dopamine in dyskinetic mice},
  journal = {Neurobiology of Disease},
  year = {2025},
  doi = {10.1016/j.nbd.2025.106968}
}
Kostenlos starten →